FierceBiotechOriginal article
{"a":[{"_":"aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug","$":{"href":"/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug","hreflang":"en"}}]}
Phase 3Negative
AI Analysis
Summary
aTyr Pharma is laying off 60% of its workforce to conserve resources for a second phase 3 attempt with a lung disease drug candidate.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Second attempt at phase 3 success
Importance:6/10
Sentiment:
-0.70
workforce reductionrestructuringphase 3 trialcost conservationlung disease
Related Companies
Read the original article
Published by FierceBiotech on August 10, 2026 4:29 AM
